New eczema pill shows promise in early safety trial

NCT ID NCT07336940

Completed Symptom relief Sponsor: Enveda Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new oral drug called ENV-294 in 9 adults with moderate-to-severe atopic dermatitis (eczema). Participants took the drug once daily for 28 days and had weekly checkups. The main goal was to see if the drug is safe and tolerable, while also looking for any changes in eczema severity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ENV-294
What this could lead to: If it works, this could point toward a new daily pill to ease symptoms of moderate-to-severe atopic dermatitis.
What could go wrong: This is a very early, small Phase 1 trial with only 9 participants. It primarily checks safety, not effectiveness. The drug may not improve symptoms or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS (AD)

Contacts and locations

Locations

Center for Dermatology Clinical Research, Inc.

Fremont, California, 94538, United States
J & S Studies

College Station, Texas, 77845, United States
Skin Sciences, PLLC

Louisville, Kentucky, 40217, United States
Texas Dermatology and Laser Specialists

San Antonio, Texas, 78218, United States
Virginia Dermatology & Skin Cancer Center

Norfolk, Virginia, 23502, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.